Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

afatinib Articles

Boehringer Ingelheim's afatinib NDA gets priority review in USA

16 January 2013

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment

1 November 2012

Analysts view Boehringer Ingelheim's first move into cancer drug market

11 October 2012

Boehringer Ingelheim files first oncology compound, afatinib, for EU approval

21 September 2012

US oncologists' perceptions of Roche's Perjeta very promising

7 September 2012

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

4 June 2012

Boehringer Ingelheim’s afatinib improves progression free survival in lung cancer patients

15 October 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS